CN101773511B - 治疗痤疮的复方外用组合药物及其制备方法 - Google Patents
治疗痤疮的复方外用组合药物及其制备方法 Download PDFInfo
- Publication number
- CN101773511B CN101773511B CN 201010108411 CN201010108411A CN101773511B CN 101773511 B CN101773511 B CN 101773511B CN 201010108411 CN201010108411 CN 201010108411 CN 201010108411 A CN201010108411 A CN 201010108411A CN 101773511 B CN101773511 B CN 101773511B
- Authority
- CN
- China
- Prior art keywords
- agent
- glycerol
- acne
- drug
- combination drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 58
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 49
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000000699 topical effect Effects 0.000 title claims abstract description 19
- 229940000425 combination drug Drugs 0.000 title claims abstract description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 48
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 31
- 239000004202 carbamide Substances 0.000 claims abstract description 30
- 235000013877 carbamide Nutrition 0.000 claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 229940040145 liniment Drugs 0.000 claims abstract description 12
- 239000000865 liniment Substances 0.000 claims abstract description 12
- 239000000499 gel Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 229960002256 spironolactone Drugs 0.000 claims abstract description 7
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims abstract description 7
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 239000002674 ointment Substances 0.000 claims abstract description 6
- 239000007921 spray Substances 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 72
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 29
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 24
- 239000003963 antioxidant agent Substances 0.000 claims description 23
- 230000003078 antioxidant effect Effects 0.000 claims description 23
- 239000002738 chelating agent Substances 0.000 claims description 23
- 229910021645 metal ion Inorganic materials 0.000 claims description 23
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229960001727 tretinoin Drugs 0.000 claims description 17
- 229960000282 metronidazole Drugs 0.000 claims description 14
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- -1 polyoxyethylene Polymers 0.000 claims description 13
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 11
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 230000002421 anti-septic effect Effects 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 229960001200 clindamycin hydrochloride Drugs 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 6
- 239000008274 jelly Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229960005053 tinidazole Drugs 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 abstract description 30
- 231100000321 erythema Toxicity 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 18
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 206010040844 Skin exfoliation Diseases 0.000 abstract description 6
- 230000035618 desquamation Effects 0.000 abstract description 6
- 239000000262 estrogen Substances 0.000 abstract description 5
- 229940011871 estrogen Drugs 0.000 abstract description 5
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000003780 keratinization Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 2
- 229940124350 antibacterial drug Drugs 0.000 abstract 2
- 239000007888 film coating Substances 0.000 abstract 2
- 238000009501 film coating Methods 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 2
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000001808 coupling effect Effects 0.000 abstract 1
- 239000010408 film Substances 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 230000036620 skin dryness Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 23
- 235000006708 antioxidants Nutrition 0.000 description 20
- 206010030113 Oedema Diseases 0.000 description 19
- 229960002227 clindamycin Drugs 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010002198 Anaphylactic reaction Diseases 0.000 description 11
- 230000036783 anaphylactic response Effects 0.000 description 11
- 208000003455 anaphylaxis Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 9
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 8
- 229960002916 adapalene Drugs 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 229960000565 tazarotene Drugs 0.000 description 7
- 229940099259 vaseline Drugs 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 231100000475 skin irritation Toxicity 0.000 description 6
- 230000036556 skin irritation Effects 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 206010048222 Xerosis Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 2
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008761 retinoic acid receptors β Proteins 0.000 description 2
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000005209 naphthoic acids Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229960004076 secnidazole Drugs 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010108411 CN101773511B (zh) | 2010-02-05 | 2010-02-05 | 治疗痤疮的复方外用组合药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010108411 CN101773511B (zh) | 2010-02-05 | 2010-02-05 | 治疗痤疮的复方外用组合药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101773511A CN101773511A (zh) | 2010-07-14 |
CN101773511B true CN101773511B (zh) | 2013-05-15 |
Family
ID=42510186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010108411 Expired - Fee Related CN101773511B (zh) | 2010-02-05 | 2010-02-05 | 治疗痤疮的复方外用组合药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101773511B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884642A (zh) * | 2010-07-30 | 2010-11-17 | 哈尔滨乐泰药业有限公司 | 一种治疗痤疮的复方乳膏及其制备方法 |
CN102600196B (zh) * | 2012-02-21 | 2013-03-27 | 江苏圣宝罗药业有限公司 | 一种用于治疗寻常痤疮的外用药物组合物 |
CN103301320A (zh) * | 2013-07-03 | 2013-09-18 | 彭中平 | 一种祛痘止痒搽剂及其配制方法 |
CN104434956B (zh) * | 2013-09-25 | 2018-10-19 | 重庆华邦制药有限公司 | 治疗痤疮、银屑病和酒糟鼻的复方制剂 |
CN104055781A (zh) * | 2014-06-16 | 2014-09-24 | 南充市中心医院 | 替硝唑螺内酯乳膏及其制备方法 |
CN113413375A (zh) | 2016-05-30 | 2021-09-21 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
CN111012688A (zh) * | 2019-12-31 | 2020-04-17 | 金日制药(中国)有限公司 | 一种具有轻医美特色的皮脂腺中痤疮丙酸杆菌等抑菌方法 |
-
2010
- 2010-02-05 CN CN 201010108411 patent/CN101773511B/zh not_active Expired - Fee Related
Non-Patent Citations (7)
Title |
---|
他扎罗汀凝胶联合克林霉素甲硝唑搽剂治疗寻常性痤疮疗效观察;蒋丽 等;《上海预防医学杂志》;20071231;第19卷(第4期);151 * |
刘巨永.痤疮的治疗进展.《河北医药》.2007,第29卷(第1期),75-76. |
复方维A酸乳膏的制备及质量控制;晏卓力 等;《中国药房》;20061231;第17卷(第4期);269-270 * |
崔福德.药剂学.《药剂学》.1980,39,172-173. * |
晏卓力 等.复方维A酸乳膏的制备及质量控制.《中国药房》.2006,第17卷(第4期),269-270. |
痤疮的治疗进展;刘巨永;《河北医药》;20070131;第29卷(第1期);75-76 * |
蒋丽 等.他扎罗汀凝胶联合克林霉素甲硝唑搽剂治疗寻常性痤疮疗效观察.《上海预防医学杂志》.2007,第19卷(第4期),151. |
Also Published As
Publication number | Publication date |
---|---|
CN101773511A (zh) | 2010-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101773511B (zh) | 治疗痤疮的复方外用组合药物及其制备方法 | |
KR100619228B1 (ko) | 국소피부전달 무수조성물 및 상기 조성물을 약제로 포함하는 국소 피부 치료용 조성물 | |
CN109745261B (zh) | 一种头皮护理液及其制备方法 | |
RU2671492C2 (ru) | Композиции, содержащие берберин или его аналоги для лечения кожных заболеваний, связанных с розацеа или с покраснением лица | |
US20040156873A1 (en) | Topically Bioavailable Acne and Rosacea Treatment Compositions | |
KR101018352B1 (ko) | 봉독을 유효성분으로 하는 여드름 예방 및 치료용 조성물 | |
CN109431873B (zh) | 一种修复舒缓皮肤炎症的组合物 | |
JP2022546928A (ja) | カンナビジオールを含む局所製剤、組成物の調製方法およびその使用 | |
JPH01503061A (ja) | 局所的メトロニダゾール製剤 | |
US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
CN113143833A (zh) | 一种护肤品及其制备方法 | |
CN108283620A (zh) | 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法 | |
CN107519236A (zh) | 一种治疗灰指甲的外用药剂 | |
CN1528328A (zh) | 治疗痤疮的复方外用药物 | |
US10123970B2 (en) | Topical retinoid solutions | |
KR102380636B1 (ko) | 피부 자극에 영향을 미치는 조성물 및 방법 | |
US9642877B1 (en) | Method of administration of chromium and magnesium sulfate for treatment of acne | |
DE19632840A1 (de) | Vitamin A-haltige Zusammensetzung | |
CN1528326A (zh) | 主治痤疮的复方外用药物 | |
CN102872158A (zh) | 一种治疗湿疹的外用药物组合物及其制备方法 | |
WO2019175902A1 (en) | A topical preparation for various skin ailments | |
Nuttall | Management of atopic dermatitis | |
US20160338985A1 (en) | Topical solution of isotretinoin | |
DE60122827T2 (de) | Wasserfreie topische Zubereitungen für die Haut | |
WO2011101868A2 (en) | Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210625 Address after: 100142 courtyard 30, Fucheng Road, Haidian District, Beijing Patentee after: AIR FORCE SPECIALTY MEDICAL CENTER OF PLA Address before: 100036 No. 30 Fu Cheng Road, Haidian District, Beijing (General Hospital of the Air Force PLA pharmacy department) Patentee before: Wu Yan Patentee before: Zhang Fucheng Patentee before: Liu Liping |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130515 |